Company intelligence / Profile preview

Yunhong Group

Wuhan, Hubei, China

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

Guozhong Xinghe Biomedical Technology develops and manufactures anti-cancer and immunomodulatory drugs, primarily using traditional Chinese medicine formulations. It claims to be at the domestic forefront for process technology and quality for its products, including fluorouracil-based topical and Brucea javanica oil oral products. Clinical stage is commercial, as products are already marketed in China[2].

Therapeutic areas: OncologyInfectious DiseasesImmunology
Modalities: Small moleculeTraditional chinese medicinePolysaccharide
Industry: Biotech

Partnerships

Huazhong University of Science and Technology (R&D support)Yunhong CTI Ltd. (affiliate focused on advanced biodegradable materials)[4][5]Yunhong Biotechnology Inc. (biodegradable materials; CE and LFGB certified)[5]

Beyond the preview

Go deeper on Yunhong Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yunhong Group.

Explore the full profile